1

Title Page

Title: Early-life enteric infection and enteropathy markers are associated with changes in adipokine, apolipoprotein and cytokine profiles later in childhood consistent with those of an adverse cardiometabolic disease risk profile in a Peruvian birth cohort.

Author names and affiliations:

Josh M. Colston - Division of Infectious Diseases and International Health, University of Virginia School of Medicine, Virginia, USA

Yen Ting Chen - Department of Emergency Medicine, Chi-Mei Medical Center, Tainan, Taiwan

Patrick Hinson - College of Arts and Sciences, University of Virginia, Virginia, USA

Nhat-Lan H. Nguyen – College of Arts and Sciences, University of Virginia, Virginia, USA

Pablo Peñataro Yori - Division of Infectious Diseases and International Health, University of Virginia School of Medicine, Virginia, USA

Maribel Paredes Olortegui - Asociación Benéfica Prisma, Unidad de Investigaciones Biomédicas, Iquitos, Peru

Dixner Rengifo Trigoso – Asociación Benéfica Prisma, Unidad de Investigaciones Biomédicas, Iquitos, Peru

Mery Siguas Salas - Asociación Benéfica Prisma, Unidad de Investigaciones Biomédicas, Iquitos, Peru

Richard L. Guerrant - Division of Infectious Diseases and International Health and Center for Global Health Equity, University of Virginia School of Medicine, Virginia, USA

Ruthly François – School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA

Margaret N. Kosek - Division of Infectious Diseases and International Health and Public Health Sciences, University of Virginia School of Medicine, Virginia, USA

Corresponding author:

Correspondence about this manuscript can be addressed to Dr. Margaret N Kosek, Division of Infectious Diseases, International Health and Public Health Sciences, Charlottesville VA, 22903 <u>mkosek@virginia.edu</u>

2

Abstract

Background: Metabolic syndrome is a cluster of risk factors for cardiovascular disease thought to afflict over a billion people worldwide and is increasingly being identified in younger age groups and socio-economically disadvantaged settings in the global south. Enteropathogen exposure and environmental enteropathy in infancy may lead to metabolic syndrome by disrupting the metabolic profile in a way that is detectable in cardiometabolic markers later in childhood.

Methods: 217 subjects previously enrolled in a birth cohort in Amazonian Peru were followed up annually from ages 2 to 5 years. Blood samples collected in later childhood were analyzed for a panel of 37 cardiometabolic biomarkers, including adipokines, apolipoproteins, cytokines, and other analytes. These were matched to extant early-life markers of enteropathy ascertained between birth and 2 years of age. Multivariate and multivariable regression models were fitted to test for associations adjusting for confounders.

Results: Fecal and urinary markers of intestinal permeability and inflammation (myeloperoxidase, lactulose and mannitol) measured from birth to 2 years of age were independently associated with later serum concentrations of soluble CD40-ligand, a proinflammatory cytokine correlated with adverse metabolic outcomes. Fecal myeloperoxidase was also strongly, directly associated with later levels of the anti-inflammatory adipocytokine omentin-1. Cumulative enteric protozoa exposure before 2 years of age showed stronger associations with later cardiometabolic markers than enteric viruses and bacteria and overall diarrheal episodes.

Conclusion: Early-life markers of enteric infection and enteropathy were associated with numerous changes in adipokine, apolipoprotein and cytokine profiles later in childhood consistent with those of an adverse cardiometabolic disease risk profile in this Peruvian birth cohort. Markers of intestinal permeability and inflammation measured in urine (lactulose, mannitol) and stool (myeloperoxidase, protozoal infections) during infancy, may predict disruptions to cytokine and adipocytokine production in later childhood that are precursors to metabolic syndrome in adulthood. Chronic enteric infections, such as by protozoan pathogens, may be more important drivers of these changes than symptomatic diarrhea or growth faltering.

Funding: Bill & Melinda Gates Foundation OPP1066146 and OPP1152146.

Keywords: Metabolic syndrome; Environmental enteropathy; Biomarkers; Cytokines; Enteric infections.

3

1 **1. Introduction**

Metabolic syndrome (MetS) refers to a cluster of risk factors for cardiovascular 2 disease (CVD) including central obesity, hyperglycemia, hypertriglyceridemia, decreased 3 high-density lipoprotein (HDL), and hypertension, which has long been recognized in adults 4 5 and has more recently become the subject of research in children and adolescents [1]. The 6 syndrome is thought to afflict over a billion people worldwide – three times the prevalence 7 of diabetes – and is increasingly being identified in younger age groups, non-obese individuals and socio-economically disadvantaged settings in the global south, once thought 8 to be protected from such conditions due to the absence of "western" lifestyle and dietary 9 patterns [2–4]. MetS confers a twofold increased 10-year risk of CVD and a fivefold increased 10 lifetime risk of developing type 2 diabetes mellitus (T2DM) [5], and there are complex, 11 multidirectional mechanisms connecting each of these conditions [6]. While MetS and its 12 13 sequalae can be managed and prevented through dietary, behavioral and lifestyle modifications, early identification and intervention is critical to avoid severe morbidities and 14 the need for pharmaceutical or surgical intervention [7]. 15

Evidence has increased over the past several decades in support of the "Barker 16 hypothesis" that many chronic and noncommunicable conditions of adulthood have 17 developmental origins - they are "programmed" by exposures encountered in childhood or 18 even in utero [8-11] and MetS may be no exception. A hypothesis is forming that the etiology 19 of this syndrome stretches into early infancy encompassing risk factors as diverse as 20 diarrhea [10], growth [12], systemic inflammation [13] and genetic and epigenetic factors 21 [2,14]. Such associations are challenging to characterize epidemiologically since they 22 operate over the length of the life course; however, numerous insights have been gained 23

4

through the follow-up of subjects at older ages who had previously been enrolled in birth 24 cohort studies as infants [10,15]. For example, DeBoer and colleagues identified a statistically 25 significant 34% increase in the odds of MetS in adulthood for every 10% increase in diarrhea 26 burden experienced in the first six months of life by following up participants in a 27 longitudinal study of growth and development in Guatemala some 30 years later [10]. Using 28 similar study designs, undernutrition and sub-optimal growth in early childhood have also 29 been shown to be associated with later life risk of CVD and glucose intolerance in both high-30 31 and lower-income countries [12].

Since the pathogenesis of MetS and its associated sequalae takes place over the life 32 33 course as a result of cumulative exposures, there is an interest in identifying subclinical precursors that can be treated as biomarkers to classify individuals at elevated metabolic 34 risk early in the disease process, facilitate early effective interventions and avert significant 35 morbidity and organ damage [16]. This need is particularly salient given the competing 36 diagnostic criteria for MetS, all of which rely on clinical features that occur late in the 37 disease progression. Numerous analytes detectable in biological samples are receiving 38 39 attention in this regard, and several have had correlations established, usually concurrently, with clinical cardiometabolic outcomes. Concentrations of apolipoproteins, 40 the transporters of lipids in the circulation, can be measured in the blood, and abnormal 41 42 values for these markers may precede dyslipidemia and other components of MetS [17]. Specifically, low concentrations of Apo-AI, a component of high-density lipoprotein 43 cholesterol (HDL), are associated with poor glucose metabolism and increased risk of CVD, 44 while apolipoprotein-B (Apo-B) is a marker of lower density lipoproteins that is more 45 reliable than LDL, and increased levels are associated with cardiovascular risk [17,18]. The 46

47	adipokines leptin and adiponectin and the ratio of the two are promising markers of MetS.
48	Pro-inflammatory cytokines including interleukin-6 (IL-6) and tumor necrosis factor alpha
49	(TNF- α) are directly associated with the risk of MetS, while anti-inflammatory cytokines -
50	IL-10, ghrelin, and antioxidant factors (PON-1) – are inversely correlated with components
51	of the cluster [16,19–22]. Several of these associations have been observed in school
52	children and adolescents as well as adults [23,24] and mirror comparable associations with
53	early childhood growth observed in a Peruvian cohort and elsewhere [25,26]. It is therefore
54	possible to explore hypotheses about the early etiology of MetS using markers like these as
55	surrogates, though there have been few published examples of this to date [13].
56	The objective of this analysis was to identify and characterize associations between
57	markers of infectious enteric disease exposure and enteropathy in the first 24 months of
58	life and adipokine, apolipoprotein and cytokine profiles in later childhood in a Peruvian
59	birth cohort. The hypothesis was that enteropathogen exposure and environmental
60	enteropathy (EE - chronic intestinal permeability and inflammation) in infancy disrupts the
61	metabolic profile in a sustained and enduring manner that is already detectable in
62	cardiometabolic markers later in childhood.

6



Figure 1: Established and hypothesized associations and causal pathways connecting early-life exposures with MetS in adolescence and adulthood and their biomarkers

7

63 2. Materials and Methods

64 **2.1.Conceptual framework:**

Figure 1 visualizes the established and hypothesized associations and causal 65 pathways connecting early-life exposures with MetS in adolescence and adulthood that 66 guided this analysis. For children raised in conditions of poor sanitation, environmental 67 exposure to enteropathogens starts early in infancy and leads to EE by disrupting normal 68 intestinal function, altering the ultrastructure and function of the delicate and complex villi 69 70 and microvilli [27]. Cumulative damage to the gut's surface increases its permeability to microbes and large molecules, provoking prolonged, low-level systemic inflammation 71 72 (detectable in disruptions to cytokine profiles), and impairing uptake and altering the utilization of nutrients, which in turn leads to impaired growth and development [25]. Over 73 the course of later childhood these processes increase adiposity and begin to irreversibly 74 impair the body's ability to metabolize glucose and lipids and signal insulin, eventually 75 increasing the risk of the individual developing MetS as they progress through adolescence 76 to adulthood [12,28]. In this analysis we tested the hypothesis that deviations from normal 77 78 levels of biomarkers of inflammation, adiposity and dyslipidemia that presage later MetS are detectable in childhood and can be identified through their associations with early-life 79 enteropathy markers. 80

81

2.2.Study population:

The Etiology Risk Factors and Interactions of Enteric Infections and Malnutrition
and the Consequences for Child Health and Development (MAL-ED) project was a multi-site
birth cohort study that ran from November 2009 to March 2014 and was established in

8

part to investigate the impact of EE on early childhood growth and development [29]. 85 Subjects were recruited and enrolled (according to criteria previously described [29]) from 86 8 communities, each in a different Low- and Middle-Income Country and monitored 87 continuously over their first 2 years of life through biweekly visits to generate a cumulative 88 and continuous history of early-life disease burden. At the MAL-ED site in Peru - the village 89 of Santa Clara de Nanay in the exurbs of Iquitos. Loreto province – contact was maintained 90 with most of the original 303 subjects beyond the initial two-year window through weekly 91 visits until 5 years of age. Santa Clara de Nanay is situated in a low-lying, tropical rainforest 92 area at the confluence of several Amazon tributaries, that is characterized by a lack of 93 infrastructure, low access to adequate water and sanitation services, and a high burden of 94 enteropathogen infection and undernutrition [25,30]. The population of the study 95 96 community are Spanish-speaking and of mixed Hispanic and Amazonian Amerindian ethnicity. 97

98

2.3.Outcome variables:

Fasting blood samples were taken from subjects at 7 and 15 months of age and then 99 annually from ages 2 to 5 years. The most recently contributed sample from each of 217 of 100 the subjects was identified and analyzed using multiplex Luminex magnetic bead panels for 101 concentrations of a panel of 37 biomarker analytes including adipokines, apolipoproteins 102 103 and cytokines (Bio-Plex Pro[™] RBM Metabolic and Hormone and Human Th17 Cytokine Assays; Milliplex[®] Human Metabolic Apolipoprotein and Hormone panels). In addition, the 104 apolipoprotein B/A-I ratio was calculated and included as a marker. For most subjects 105 (72% of those contributing any blood samples), a sample collected at the target age of 5 106

9

107	years was available for inclusion, otherwise samples from the target ages of 2, 3 or 4 years
108	(22%) or, for a minority of subjects (6%), 15 months were used.

109 **2.4.Exposure variables:**

110 The following primary exposure variables were taken from extant data collected111 from the subjects between birth and 2 years of age as part of the MAL-ED study:

Biomarkers of Enteropathy: The following biomarkers were included based on 112 their hypothesized and documented associations with EE and growth outcomes in this 113 cohort and elsewhere [25,27,31]: seven serum biomarkers – adiponectin (ug/mL), ferritin 114 (FRTN - ng/mL), interleukin-8 (IL-8 - pg/mL), proline, Serum Amyloid P-Component (SAP -115 ug/mL), serotransferrin (Transferrin - mg/dl), and tryptophan (umol/L) – measured in 116 blood samples taken at 7, 15 and 24 months by previously described methods [25]; three 117 fecal biomarkers—alpha-1-antitrypsin (AAT-mg/g), myeloperoxidase (MPO-ng/mL) and 118 119 neopterin (NEO-nmol/L) - measured in monthly stool samples by ELISA; and the percent urinary lactulose and mannitol recovery as measured by intestinal permeability tests 120 performed on urine samples collected at 3, 6, 9, 15 and 24 months following an oral 121 lactulose and mannitol dosing as previously reported [32], and the lactulose:mannitol ratio 122 was calculated and expressed as standardized as Z-scores (LMZ) relative to a low-EE 123 reference population [33]. 124

Nutritional status: Length- and weight-for-age Z scores (LAZ, WAZ) recorded at
 monthly anthropometric assessments were included as well as birthweight as a marker of
 nutritional status *in utero*.

10

128	<i>Cumulative enteropathogen exposure:</i> Stool samples collected at monthly
129	intervals and during caregiver-reported diarrheal episodes were tested for the presence of
130	numerous enteropathogen species using quantitative PCR, enzyme-linked immunosorbent
131	assay (ELISA), and microscopy methods [34,35]. The pathogens with highest attributable
132	morbidity, were summed over the two-year follow-up period for three taxa – viruses
133	(adenovirus, astrovirus, norovirus, rotavirus, and sapovirus), bacteria (Aeromonas spp.,
134	Campylobacter spp., Salmonella spp., Shigella spp., Plesiomonas spp., Vibrio spp., and various
135	pathotypes of Escherichia coli), and protozoa (Cryptosporidium spp., Entamoeba histolytica,
136	and <i>Giardia</i> spp.). Samples from the same subject that were positive for the same pathogen
137	were considered discrete infection episodes if separated either by an intermediate negative
138	sample or a period of 14 days, with the exception of <i>Campylobacter</i> spp. and norovirus, for
139	which a period of 30 days was used, and the 3 protozoa for which 3 intermediate negative
140	samples were required (criteria previously documented by Colston and colleagues [36]).
141	The total number of diarrhea episodes was also included.
142	A minimal set of covariates were used in the analysis to adjust for potential
143	confounding including sex, household income, and age at outcome ascertainment
144	(dichotomized at 48 months). The definitions and distributions of the exposures and
145	covariates are presented in table 2.
146	2.5.Statistical analysis:
	-

All biomarkers' values were log-transformed with base 2 so that each 1 unit
increase in effect size estimate was interpreted as that incurred by a doubling in biomarker
concentration. Because the Luminex bead panel can only detect analyte concentrations

11

within certain ranges of values that vary by analyte and subject age, many biomarkers had 150 151 values that were above or, more commonly, below the limits of detection for the assay, and in some cases, these were a significant proportion of the overall data. Biomarkers for which 152 more than 40% of the original values were missing were excluded from further analysis 153 [25]. For all other biomarkers, values that were outside of the range of detection were 154 imputed using interval regression, a method used for partially observed data with values 155 that are missing due to being censored at known upper and lower limits, but are assumed 156 157 to follow the distribution of the fully observed values [37]. For the EE biomarkers and nutritional status exposures (apart from birthweight) the within-subject average value was 158 159 calculated across all available observations in the birth to 2-year age window, while for the enteropathogen infection and diarrhea episodes, the total was used to approximate 160 cumulative exposure. These extant summary exposure measures were matched to the later 161 outcome biomarker concentrations from the same subjects. 162

Correlations between the MetS serum biomarker outcomes and the early-life 163 exposures were plotted in a correlation matrix heatmap. A multivariate regression model 164 165 was then fitted to jointly model associations between the multiple early-life markers and each of the MetS biomarkers adjusting for the covariates. To assess the statistical 166 167 significance of each exposure's association with the entire set of biomarker outcomes, and vice versa, *p*-values from Wald tests of the combined significance of the relevant coefficient 168 estimates were compared to a Bonferroni-corrected threshold of $\alpha = 0.05/m$ where m is 169 either the number of outcomes or the number of early-life markers depending on which is 170 being jointly tested. Finally, a subset of early-life markers was selected based on the 171 significance and strength of their associations across multiple outcomes and included, with 172

12

173	the same covariates, in a series of final regression models for each of the MetS biomarker
174	outcomes. For the initial multivariate model, exposures were standardized so that their
175	coefficients were on a similar scale and could be easily compared across multiple early-life-
176	MetS marker pairings, whereas for the final multivariable models, they were kept on their
177	original scale for ease of interpretation. The coefficients from the final models were
178	visualized in a dot-and-whisker plot. Analyses were carried out using Stata 16 [38] and R
179	3.6.2 [39].

180 **2.6.Data statement:**

181 At the time this article was submitted to the journal there were restrictions to the 182 availability of the data used in the analysis. Readers wishing to request access to the data 183 should contact the corresponding author.

13

184 **3. Results**

Table 1 shows the definitions and categories of the variables included in the 185 analysis. Summary statistics of the variables, including all candidate serum MetS 186 biomarkers available for this analysis and their documented associations with individual 187 MetS components based on a review of the published scientific literature, are presented in 188 tables S1 and S2 in the supplementary materials. Samples from 217 subjects were analyzed 189 for biomarkers including adipokines, apolipoproteins, cytokines, hormones, peptides, 190 proteins, and an enzyme. Prior to applying the exclusion criteria, 37 distinct MetS 191 biomarkers were initially considered for inclusion in further analysis. Fourteen analytes -192 amylin, ghrelin, glucagon-like peptide 1 (GLP-1), glucagon, interferon gamma (IFN- γ), 193 interleukins 1β, 4, 6, 10, 17A, 22, 23 and 33, and Peptide Tyrosine Tyrosine (TYY) - were 194 excluded from further analysis due to more than 40% of their original values being missing 195 196 (mostly due to their concentrations being below the quantifiable range for the assay). The 23 analytes that met the inclusion criteria of retaining more than 60% of their original 197 values included all of the apolipoproteins (Apo), the adipokines C-peptide, Fibroblast 198 Growth Factors 21 and 23 (FGF21 and FGF23), Galectin-3 (Gal-3), Gastric Inhibitory 199 Polypeptide (GIP), insulin, leptin, omentin-1, Pentraxin 3 (PTX3), Paraoxonase-1 (PON1), 200 Pancreatic Polypeptide (PP), Soluble Leptin Receptor (sOB-R), and Visceral Adipose Tissue-201 Derived Serpin (Vaspin), and the cytokines Monocyte Chemoattractant Protein-1 (MCP-1), 202 Soluble CD40-ligand (sCD40L), and Tumor Necrosis Factor Alpha (TNF- α). Of these, 5 203 (omentin-1, ApoA-I, PON1, sOB-R and PP) have a documented inverse association with 204 MetS components overall, while the remaining 18 had direct associations previously 205 reported in the literature. 206

14

Table 1: Definitions of early-life enteropathy markers, later childhood MetS markers that met the criteria for inclusion in the analysis, and covariates

A. Eai	rly-life (0 – 2 years of age) enteropathy markers	Calculation
	i. Serum markers:	
	Adiponectin, ferritin (FRTN), Interleukin (IL)-8, proline, Serum Amyloid P-Component (SAP), transferrin, and tryptophan	Within-subject mean of concentrations measured at 7, 15 & 24 months of age.
ii	i. Fecal markers:	
	Alpha-1-antitrypsin (AAT), myeloperoxidase (MPO), and neopterin (NEO)	Within-subject mean of concentrations measured in monthly, non-diarrheal stools from ages 0 – 24 months
ii	ii. Urinary markers:	
	Percent urinary lactulose and mannitol recovery	Within-subject mean of results measured at 3, 6, 9, 15 & 24 months of age
	Z-scores of Lactulose:mannitol ratio (LMZ) relative to reference population	Within-subject mean of results measured at 3, 6, 9 & 15 months of age [‡]
iv.	Anthropometric markers:	
	Length- and weight-for-age Z scores	Within-subject means of monthly measurements from ages 0 – 24 months
	Birth weight	Weight at birth
v. E	Enteropathogen exposure markers:	
	Viral, bacterial, protozoal infection and diarrheal episodes	Within-subject total infections diagnosed in monthly and diarrheal stools from ages 0 – 24 months
B. Lat	ter childhood (2 – 5 years of age) MetS biomarkers	
i. A	Apolipoproteins:	
	ApoA-I*, ApoA-II, ApoB, ApoB/ApoA-I ratio, ApoC-II, ApoC-III, ApoE	Concentration in most recent available blood sample
ii. A	Adipokines:	
	C-peptide, Fibroblast Growth Factors 21 and 23 (FGF21 and FGF23), Galectin-3 (Gal-3), Gastric Inhibitory	
	Polypeptide (GIP), insulin, leptin, omentin-1*, Pentraxin 3 (PTX3), Paraoxonase-1 (PON1)*, Pancreatic Polypeptide (PP)*, Soluble Leptin Receptor (sOB-R)*, and Visceral Adipose Tissue-Derived Serpin (Vaspin)	Concentration in most recent available blood sample
iii. C	Polypeptide (GIP), insulin, leptin, omentin-1*, Pentraxin 3 (PTX3), Paraoxonase-1 (PON1)*, Pancreatic Polypeptide (PP)*, Soluble Leptin Receptor (sOB-R)*,	
iii. C	Polypeptide (GIP), insulin, leptin, omentin-1*, Pentraxin 3 (PTX3), Paraoxonase-1 (PON1)*, Pancreatic Polypeptide (PP)*, Soluble Leptin Receptor (sOB-R)*, and Visceral Adipose Tissue-Derived Serpin (Vaspin)	
	Polypeptide (GIP), insulin, leptin, omentin-1*, Pentraxin 3 (PTX3), Paraoxonase-1 (PON1)*, Pancreatic Polypeptide (PP)*, Soluble Leptin Receptor (sOB-R)*, and Visceral Adipose Tissue-Derived Serpin (Vaspin) Cytokines: Monocyte Chemoattractant Protein-1 (MCP-1), Soluble CD40-ligand (sCD40L), and Tumor Necrosis Factor	blood sample Concentration in most recent available
C. Cov	Polypeptide (GIP), insulin, leptin, omentin-1*, Pentraxin 3 (PTX3), Paraoxonase-1 (PON1)*, Pancreatic Polypeptide (PP)*, Soluble Leptin Receptor (sOB-R)*, and Visceral Adipose Tissue-Derived Serpin (Vaspin) Cytokines: Monocyte Chemoattractant Protein-1 (MCP-1), Soluble CD40-ligand (sCD40L), and Tumor Necrosis Factor Alpha (TNF-α)	blood sample Concentration in most recent available
C. Cov	Polypeptide (GIP), insulin, leptin, omentin-1*, Pentraxin 3 (PTX3), Paraoxonase-1 (PON1)*, Pancreatic Polypeptide (PP)*, Soluble Leptin Receptor (sOB-R)*, and Visceral Adipose Tissue-Derived Serpin (Vaspin) Cytokines: Monocyte Chemoattractant Protein-1 (MCP-1), Soluble CD40-ligand (sCD40L), and Tumor Necrosis Factor Alpha (TNF- α) variates	blood sample Concentration in most recent available

associations.

‡ LMZ could not be calculated at 24 months, as reference values were not available at that age.

207	Figure 2 shows a heatmap matrix of the Spearman coefficients for the correlations
208	between each of the included serum MetS biomarkers with each other and with the early-
209	life enteropathy markers. As expected, correlations between markers in early-life
210	exposures with those measured later in childhood tended to be weaker than those between
211	the later life biomarkers and each other. Notable exposure-outcome correlations include
212	that of fecal MPO concentration, an acute intestinal inflammation marker, directly with
213	omentin-1 and inversely with sCD40L, as well as WAZ-score with leptin. Among the
214	correlations between MetS markers, the apolipoproteins demonstrated strong direct
215	correlations exclusively with each other. Other strong correlations included C-peptide
216	directly with both GIP and insulin and the inverse correlation of omentin-1 with sCD40L.



Figure 2: Heatmap matrix of the correlations between each of the included serum MetS biomarkers with each other and the early-life enteropathy markers

17

The heatmap matrix in figure 3 shows the coefficient estimates from a multivariate 217 linear regression model of the associations between the set of standardized early-life 218 markers and the cardiometabolic biomarker outcomes in late childhood adjusting for the 219 covariates sex, income, and age at follow-up. The serum biomarkers are ordered along the 220 y-axis according to the strength and direction of their documented association with MetS 221 based on the review of the literature. Multiple early-life exposure markers showed strong 222 or statistically significant associations with the biomarker outcomes measured in later 223 childhood. By far the largest effect sizes observed were the direct association of urinary 224 lactulose with sCD40L, and the corresponding inverse association between urinary 225 226 mannitol with that same cytokine. For numerous other MetS biomarkers, the effects for lactulose compared to mannitol were similarly in opposing directions, while for the LMZ-227 228 score (calculated from the two urinary biomarkers, but unavailable for 24-month samples due to lack of standard reference values at that age), no strong or statistically significant 229 effects were observed for any MetS biomarker. sCD40L was also strongly inversely 230 associated with IL-8, proline, MPO, and protozoal infections and was statistically significant 231 at the Bonferroni-adjusted α level across the entire set of exposures. Other outcomes that 232 were statistically significant by the same criterion included TNF- α and omentin-1. 233 respectively the biomarkers with the strongest direct and the strongest inverse 234 associations with MetS documented in the literature by our assessment, as well as leptin. 235 236 The most statistically significant effect of any single early-life-later childhood marker pairing was the direct association between MPO and omentin-1. While MPO also showed 237 strong inverse associations with MCP-1 as well as sCD40L and leptin and a direct effect on 238 FGF21, the marker did not retain statistical significance at the Bonferroni-adjusted α level 239

- 240 across the entire set of MetS biomarkers. Proline, transferrin, and total protozoal infections
- 241 were the only early-life markers that met this criterion of correction for multiple
- comparisons, the latter showing strong inverse associations with MCP-1, sCD40L, leptin
- and ApoA-I, and direct associations with insulin, PP and sOB-R.



Figure 3: Heatmap matrix of the coefficients from a multivariate regression model of the associations of multiple, standardized early-life enteropathy markers with MetS biomarkers later in childhood – ordered by the strength and direction of their documented association with metabolic syndrome (MetS) - adjusting for sex, income, and age at follow-up. Unadjusted significance levels for individual coefficients are indicated with dots (••• p<0.001, •• p=0.001-0.01, • p=0.01-0.05) and combinations of outcomes and exposures that were significant at the Bonferroni-adjusted $\alpha \le 0.05/m$ level according to the Wald test are outlined.

20

The subset of six early-life markers selected for inclusion in the final regression 244 models consisted of fecal MPO, percent urinary lactulose and mannitol recovery, serum 245 proline and transferrin and total protozoal infections, the latter rescaled so that the 246 coefficients represent the effects of a 10-infection increment. Figure 4 plots the coefficient 247 estimates from the models fitted for the subset of early-life markers on each of the log₂ 248 MetS biomarker concentrations adjusting for the covariates. As in the multivariate model, 249 the effects of lactulose and mannitol on sCD40L were among the largest identified (though 250 251 no longer the largest overall) and almost equivalent in magnitude but in opposite directions, a doubling in lactulose recovery associated with a more than two thirds increase 252 253 (0.68 [0.08, 1.28]) and the equivalent increase in mannitol with a similarly sized decrease (0.59 [-1.17, -0.02]) in sCD40L concentrations in later childhood. MPO and proline 254 255 concentrations in infancy also had large inverse effects on later sCD40L levels respectively a decrease of 1.08 (-1.70, -0.46, the largest effect size identified by the final 256 models) and 0.75 (-1.47, -0.03) in log₂ concentrations for each one-unit increase – as did 257 total protozoal infections, though in the latter case the confidence intervals for the estimate 258 narrowly spanned the null value. 259

The effect of early-life MPO on later omentin-1 levels remained the most statistically
significant association identified in the final models. An increase in omentin-1,

concentrations of almost two thirds (0.61 [0.33, 0.88], *p* = 0.00002) was identified for every
doubling in MPO levels, though none of the other 5 enteropathy markers in the final subset
showed significant effects on omentin-1. MPO also showed large direct effects on FGF21
and C-Peptide and smaller effects on sOB-R and ApoA-II as well as indirect effects on
sCD40L, leptin and MCP-1. In addition to sCD40L, mannitol showed smaller-magnitude

267	inverse associations with MCP-1, Gal-3 and PTX3 (the latter not significant at the α = 0.05
268	level), and small direct associations with ApoA-II, C-Peptide and PON1, while for lactulose
269	the only other biomarker to show a statistically significant association apart from sCD40L
270	was FGF21, the larger of the two effect sizes (0.72 [0.17, 1.27]). Serum proline
271	concentration measured in early life demonstrated inverse associations with several later-
272	life biomarkers that are directly associated with MetS, notably insulin (-0.70 [-1.18, -0.22])
273	and sCD40L (-0.75 [-1.47, -0.01]) – and a direct association with PON1 (0.56 [0.11, 1.03]),
274	which is itself directly associated with MetS.
275	An increase in 10 total protozoal infections between ages 0-2 years was associated
276	with a more than 50% increase in PP (0.57 [0.11, 1.03]) and a one-third decrease in ApoA-I
277	(-0.33 [-0.59, -0.09]), as well as a notable increase in insulin concentration and decreases in
278	sCD40L and FGF23, though the latter three with confidence intervals that narrowly
279	included the null value. Although it was one of just two early-life markers to be statistically
280	significant at the Bonferroni-adjusted $lpha$ -level in the initial multivariate regression,
281	transferrin only showed associations with ApoB (0.33 [0.02, 0.64]) and ApoA-I (0.28 [0.01,
282	0.55]) that were significant at the at the α = 0.05 level in the final models, though large
283	direct effects on leptin, insulin and PTX3 and an indirect effect on vaspin were also
284	observed. Similarly, though TNF- $lpha$ had been significantly associated with the full early-life
285	marker panel in the multivariate model, it only showed a small, statistically significant
286	association with proline in the final subset (-0.22 [-0.43, -0.01]).



Figure 4: Coefficient estimates from regression models fitted for a subset of six early-life exposures – myeloperoxidase (MPO), percent urinary lactulose and mannitol recovery, serum proline and transferrin and protozoal infections (scaled so the effect is for an increase in 10 infections) - on each of the cardiometabolic biomarker outcomes adjusting for sex, income, and age with 95% confidence intervals and significance levels. Outcomes are grouped by the documented direction of their associations with metabolic syndrome (direct or inverse).

23

287 4. Discussion

There is an urgent need to clarify the mechanisms that link enteric infections and EE 288 in infancy with MetS later in life in a way that can inform intervention early in the disease 289 process before significant end-organ damage and morbidity occur [16]. It is plausible that 290 the documented associations between diarrhea in early infancy, undernutrition in early 291 childhood, and MetS later in life are partially mediated by EE. Further evidence for this 292 hypothesis comes from the observations that MetS is highly prevalent even in low-resource 293 settings with high enteropathogen burdens and an absence of lifestyle risk factors, and that 294 obesity and liver steatosis are associated with concurrent intestinal permeability in adults 295 [40,41]. Hypothesized pathways by which EE in infancy may be linked to subsequent MetS 296 in childhood and beyond include depressed apolipoprotein production causing 297 dyslipidemia and inflammation due to bacterial or lipopolysaccharide translocation [13]. 298 However, the magnitude and relative clinical significance of these pathways have yet to be 299 characterized. This study represents an initial attempt to investigate the associations 300 301 between markers of early-life environmental exposures and adipokine, apolipoprotein and cytokine profiles later in childhood. It is also the first to report the distributions of this 302 large panel of biomarkers in a cohort of young children. 303

According to our conceptual framework the earliest metabolic alterations may
 manifest as disruptions to cytokine profiles. While many cytokines that were tested for in
 this cohort could not be included due to having too many values outside the detectable
 range (e.g., IFN-γ and various interleukins), three that were included (MCP-1, sCD40L and
 TNF-α) demonstrated notable associations with numerous early-life enteropathy markers.

24

In particular, concentrations of sCD40L, a proinflammatory cytokine shown to be positively 309 correlated with concurrent insulin resistance, BMI and waist circumference [42,43], was 310 strongly associated with lactulose and mannitol in opposite directions but not with Z-311 scores of the L:M ratio, the more commonly used way of expressing these markers as an 312 indicator of intestinal absorption and permeability [44]. The L:M Z-scores did not include 313 data from 24-months due to the lack of available standard values at that age, which may 314 contribute to the difference in effect compared with the two component biomarkers 315 individually. As a larger, disaccharide molecule, lactulose is absorbed in greater 316 proportions when permeability is high due to mucosal cell damage, while the 317 318 monosaccharide mannitol is instead absorbed in direct proportion to the healthy mucosal absorptive area [32,44]. Consequently, inflammatory bowel syndromes (such as Crohn's 319 320 disease) are associated with higher excretion of urinary lactulose, conditions characterized by flattening of the villi (e.g., Celiac disease) with lower mannitol [45], and both 321 enteropathies are associated with elevated sCD40L levels [46,47]. This analysis also 322 identified similar inverse associations between mannitol and both PTX3 and MCP-1, which, 323 like sCD40L, are inflammatory markers themselves correlated with adverse MetS outcomes 324 [48,49]. 325

Potential biomarkers of increased adiposity that were available for this analysis include the pro-inflammatory adipokines leptin, vaspin, FGF21, and TNF- α (the latter also a cytokine), which are known to increase as a result of the interacting effect of central obesity with the other four MetS components (hyperglycemia, hypertriglyceridemia, dyslipidemia, and hypertension) [21]. The direct association between diarrhea episodes and TNF- α in the multivariate analysis may constitute further evidence that previously

25

documented links between diarrhea in early childhood and MetS in adulthood may be 332 mediated by increased adiposity with EE as its etiology [14]. Specifically, EE may disrupt 333 metabolic function through pathways other than increased intestinal permeability, such as 334 through increased adiposity as a result of elevated energy harvest caused by gut dysbiosis 335 [28]. However, the strong effect of both urinary lactulose and fecal MPO on FGF21, an 336 adipokine associated with increased intestinal permeability in mice and obesity in humans, 337 suggests a complex interrelationship between these risk factors in the early pathogenesis 338 339 of MetS [50,51].

As biomarkers of lipid metabolism, we hypothesize that disruptions to 340 341 apolipoproteins become apparent later in the MetS pathogenesis than for cytokines and adipokines (figure 1), accompanying later stage adverse metabolic adaptations [52,53]. 342 Nevertheless, some small-magnitude associations with early-life exposures were observed 343 here even for apolipoproteins measured in childhood, though only for ApoA-I (directly with 344 transferrin, inversely with protozoal infections), ApoA-II (directly with MPO and mannitol, 345 inversely with proline), ApoB (directly with transferrin), and ApoC-II (directly with 346 347 mannitol). Notably, the ApoB/ApoA-I ratio, thought to be a better predictor of insulin resistance and MetS than any single lipid fractions [53], showed no associations with early-348 life markers, while for its two component analytes several associations in the same 349 direction were observed. These simultaneous positive associations with transferrin, which 350 is directly correlated with infant growth in this cohort [25], suggest that both ApoA-I and 351 ApoB in children from EE-endemic settings may predict nutritional status, since loss of 352 353 intestinal surface area is associated with decreased levels of both apolipoproteins [13].

26

While these results appear consistent with the conceptual framework outlined in 354 figure 1, others appear to be at odds with prior hypotheses and findings. Fecal MPO - a 355 lysosomal protein found in neutrophils that is used as a marker of oxidative stress induced 356 by inflammatory bowel disease (IBD) and EE and is predictive of subsequent growth 357 faltering in young children [25,27,54,55] – had an inverse association with sCD40L that 358 was larger and more statistically significant than that of mannitol, as did proline, another 359 documented predictor of poor growth and oxidative damage [25,56]. Previous findings 360 have shown plasma sCD40L to be positively correlated with concurrent levels of 361 inflammatory chemokines [57]; so, it is unclear why IL-8, as well as oxidative stress 362 363 markers (MPO and proline), would be negatively associated with later levels of the cytokine in this study. Furthermore, the most statistically significant association found here 364 365 was the direct effect of MPO on omentin-1, an anti-inflammatory adipocytokine known for being inversely correlated with weight loss, beneficial for insulin-sensitizing and 366 vasodilation and protective against metabolic and other disorders [58,59]. However, it is 367 now understood that omentin-1 is also an acute-phase, anti-inflammatory reactant, and 368 therefore may increase in the initial stages of disease and as a response to inflammation 369 [59]. Omentin-1 also has a protective role against oxidative stress, such as is produced by 370 371 MPO-induced cell injury [60], which may explain the positive association between these two markers in our analysis. Since oxidative stress is closely implicated in the pathogenesis 372 373 of atherosclerosis in MetS, assessing both markers in combination may be clinically relevant and necessary for predicting adverse health outcomes. This is consistent with 374 375 previous findings that intestinal T regulatory cells are activated and more abundant in children with active IBD than healthy controls [61]. 376

27

Previous longitudinal studies have shown a link between poor early childhood 377 growth and increased incidence of CVD [62] and glucose intolerance [63] later in life. The 378 fact that significant associations were observed for biochemical enteropathy markers but 379 not for the anthropometric indicators in this study suggests that EE may impact later 380 metabolic outcomes via mechanisms that operate independently of nutritional status and 381 for which growth is a marker, rather than a mediator. In contrast to previously published 382 findings, we did not find strong associations between diarrhea episodes in early childhood 383 and later MetS markers [10] and of the three pathogen taxa assessed, only cumulative 384 protozoal infections showed substantial effects on the later biomarkers and mostly only in 385 the multivariate model, such as increases in insulin, PP and sOB-R and decreases in leptin, 386 MCP-1, sCD40L, and ApoA-I concentrations. sCD40L protects against protozoal infections 387 388 through its interaction with CD40 promoting cell-mediated immunity [64], while leptin mediates resistance to *E. histolytica* [65]; so, it is possible that these infections are acting as 389 a marker of chronic deficiency in these two cytokines that lasts through childhood. 390 However, leptin is secreted by colonic epithelial cells during acute inflammation and both 391 micro and macro parasitic intestinal infections can disrupt its production [66–68], so, a 392 causative relationship is also plausible. Leptin and its binding protein sOB-R are 393 394 reciprocally regulated [69], explaining these two analytes' inverse correlation and opposing associations with protozoal infections in this cohort and with MetS in previous 395 396 literature. The chemokine MCP-1 is involved in the intestinal inflammatory immune response against infection with various pathogens and in this study, we demonstrate an 397 increase in enteric protozoal infections associated with lower serum MCP-1 for the first 398 time in a human population (figure 3) [70]. While this apparent suppression of pro-399

28

inflammatory cytokines MCP1 and sCD40L due to protozoal infections may at first sight 400 401 seem surprising, previous studies have documented diminished inflammatory immune responses following repeated intestinal parasite infections, perhaps as an immune 402 tolerance response to prevent further tissue damage [71]. Such a downmodulation 403 mechanism may also underlie the equally surprising inverse associations of IL-8, MPO and 404 proline with sCD40L. The direct association between cumulative protozoal infections and 405 PP suggests that the loss of appetite that is a common symptom of those infections may be 406 mediated, as opposed to compensated for, by the appetite suppressing peptide [72]. The 407 strong direct association between protozoal infections and blood insulin levels appears to 408 have no precedent in prior literature. A possible explanation for protozoal infections 409 showing more associations with later outcomes than viruses and bacteria may be that they 410 411 are more prone to longer, chronic infections, suggesting that cumulative duration of infection may be more important than the number of discrete infection episodes. 412

This analysis was subject to several limitations. Not only were numerous cytokines 413 that circulate at very low concentrations not able to be quantified in the cohort, but other 414 415 biomarkers of documented relevance were also unavailable, such as the adiponectin-leptin ratio [73], since adiponectin was only measured in the early-life assessments, and leptin at 416 417 outcome ascertainment. Furthermore, as with any cohort study, the possibility that those subjects retained under surveillance differed systematically from those lost to follow-up is 418 a potential source of bias that should be considered when interpreting these findings. The 419 principal limitation, however, is the relatively short interval that elapsed between 420 421 ascertainment of the exposures and outcomes. Although MetS is increasingly recognized as manifesting in childhood, the subjects in this study may have still been too young at the 422

29

time of follow-up (\leq 5 years) for the precursors of the conditions to have become fully 423 apparent. This may explain why many of the effect sizes identified here were small in 424 magnitude; however, the fact that they were apparent at all and statistically significant 425 even in mid-childhood is itself striking. We anticipate that these divergences in metabolic 426 profiles will continue into adolescence and beyond and be accelerated by puberty and the 427 accompanying increases in insulin, growth hormone and IGF-I secretion, changes in body 428 composition and slowing of metabolism [74]. This highlights the need for longer follow-up 429 at multiple stages of the life course in this and other cohorts. 430

431 **5. Conclusions**

In conclusion, early-life enteric infection and enteropathy markers are associated 432 with numerous changes in adipokine, apolipoprotein and cytokine profiles later in 433 childhood consistent with those of an adverse cardiometabolic disease risk profile in this 434 Peruvian birth cohort. In particular, markers of intestinal permeability and inflammation 435 measured in urine (lactulose, mannitol) and stool (MPO, protozoal infections) during 436 437 infancy, may predict disruptions to cytokine and adipocytokine production in later childhood that are precursors to MetS in adulthood. Chronic or recurring enteric infections, 438 such as by protozoan pathogens, may be more important drivers of these changes than 439 symptomatic diarrhea or growth faltering. 440

30

441 **6. Acknowledgements**

We wish to thank participants, their families and the study community for their dedicated
time and effort to better the understanding the transmission and more enduring impact of
enteric infections is early childhood.

445 **7. Author contributions**

446 **Josh Colston:** Conceptualization, methodology, formal analysis, writing – original draft,

447 visualization, supervision. Yen Ting Chen: Formal analysis, investigation, writing – original

448 draft. **Patrick Hinson:** Formal analysis, visualization. **Nhat-Lan Nguyen:** Writing – original

449 draft. Pablo Yori: Investigation, supervision. Maribel Olortegui: Investigation,

450 supervision. Dixner Trigoso: Investigation. Mery Salas: Investigation. Richard Guerrant:

451 Conceptualization, writing – review and editing. Ruthly Francois: Investigation, writing –

452 review and editing. Margaret Kosek: Conceptualization methodology, writing – review

453 and editing, supervision, funding acquisition.

454 8. Funding Sources

The Etiology, Risk Factors, and Interactions of Enteric Infections and Malnutrition and the Consequences for Child Health and Development Project (MAL-ED) is carried out as a collaborative project supported by the Bill & Melinda Gates Foundation (BMGF - 47075), the Foundation for the National Institutes of Health, and the National Institutes of Health, Fogarty International Center while additional support was obtained from BMGF for the examination of host innate factors on enteric disease risk and enteropathy (grants OPP1066146 and OPP1152146 to MNK). Additional funding was obtained from the

31

- 462 Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases of the Johns
- 463 Hopkins School of Medicine.

464 9. Conflict of interests

- 465 The authors report no conflicts of interest. The information has not previously been
- 466 published or presented in any meetings.

467 **10. Ethical standards**

- 468 Ethical approval for MAL-ED was given by the Johns Hopkins Institutional Review Board as
- 469 well as the Ethics Committee of Asociacion Benefica PRISMA, and the Regional Health
- 470 Department of Loreto;

32

471 **11. References**

- 1. Magge SN, Goodman E, Armstrong SC. The Metabolic Syndrome in Children and
- 473 Adolescents: Shifting the Focus to Cardiometabolic Risk Factor Clustering. Pediatrics
- 474 [Internet]. 2017;140:e20171603. http://www.ncbi.nlm.nih.gov/pubmed/28739653:
- 475 Accessed: 2019 Apr 15
- 476 2. Saklayen MG. The Global Epidemic of the Metabolic Syndrome. Curr. Hypertens. Rep.
- 477 Current Medicine Group LLC 1; 2018.
- 478 3. Kiama CN, Wamicwe JN, Oyugi EO, Obonyo MO, Mungai JG, Roka ZG, et al. Prevalence and
- 479 factors associated with metabolic syndrome in an urban population of adults living with
- 480 HIV in nairobi, Kenya. Pan Afr. Med. J. African Field Epidemiology Network; 2018;29.
- 481 4. Friend A, Craig L, Turner S. The prevalence of metabolic syndrome in children: A
- 482 systematic review of the literature. Metab. Syndr. Relat. Disord. 2013. p. 71–80.
- 483 5. Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al.
- 484 Harmonizing the metabolic syndrome: A joint interim statement of the international
- diabetes federation task force on epidemiology and prevention; National heart, lung, and
- 486 blood institute; American heart association; World heart federation; International .
- 487 Circulation. 2009. p. 1640–5.
- 488 6. Younossi ZM. The epidemiology of nonalcoholic steatohepatitis. Clin. Liver Dis. [Internet].
- 489 John Wiley and Sons Inc.; 2018;11:92–4. http://doi.wiley.com/10.1002/cld.710: Accessed:
 490 2020 May 13
- 491 7. Al-Hamad D, Raman V. Metabolic syndrome in children and adolescents. Transl. Pediatr.

- 492 [Internet]. AME Publications; 2017;6:397–407.
- 493 http://www.ncbi.nlm.nih.gov/pubmed/29184820: Accessed: 2019 Apr 12
- 494 8. Barker DJP. Adult consequences of fetal growth restriction. Clin. Obstet. Gynecol. Clin
- 495 Obstet Gynecol; 2006. p. 270–83.
- 496 9. Barker DJP. Fetal programming of coronary heart disease. Trends Endocrinol. Metab.
- 497 Trends Endocrinol Metab; 2002. p. 364–8.
- 498 10. DeBoer MD, Chen D, Burt DR, Ramirez-Zea M, Guerrant RL, Stein AD, et al. Early
- 499 childhood diarrhea and cardiometabolic risk factors in adulthood: The Institute of
- 500 Nutrition of Central America and Panama Nutritional Supplementation Longitudinal Study.
- 501 Ann. Epidemiol. [Internet]. 2013;23:314–20.
- 502 http://www.ncbi.nlm.nih.gov/pubmed/23608305: Accessed: 2020 Apr 21
- 503 11. Edwards M. The Barker Hypothesis BT Handbook of Famine, Starvation, and Nutrient
- 504 Deprivation: From Biology to Policy. In: Preedy V, Patel VB, editors. Springer International
- 505 Publishing; 2017. p. 1–21. https://doi.org/10.1007/978-3-319-40007-5_71-1: Accessed:
- 506 2020 Jun 1
- 507 12. DeBoer MD, Lima AAMA, Oría RB, Scharf RJ, Moore SR, Luna MA, et al. Early childhood
- 508 growth failure and the developmental origins of adult disease: do enteric infections and
- 509 malnutrition increase risk for the metabolic syndrome? Nutr. Rev. [Internet]. Blackwell
- 510 Publishing Inc.; 2012;70:642–53.
- 511 http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3493112&tool=pmcentrez&r
- 512 endertype=abstract: Accessed: 2015 Nov 24

24

	34
513	13. Lee GO, Olortegui MP, Salas MS, Yori PP, Trigoso DR, Kosek P, et al. Environmental
514	enteropathy is associated with cardiometabolic risk factors in Peruvian children. J. Dev.
515	Orig. Health Dis. [Internet]. 2017;8:337–48.
516	http://www.ncbi.nlm.nih.gov/pubmed/28264759: Accessed: 2019 Apr 12
517	14. Guerrant RL, Deboer MD, Moore SR, Scharf RJ, Lima AAM. The impoverished gut - A
518	triple burden of diarrhoea, stunting and chronic disease. Nat. Rev. Gastroenterol. Hepatol.
519	Nature Publishing Group; 2013;10:220–9.
520	15. Fall CHD, Sachdev HS, Osmond C, Lakshmy R, Biswas SD, Prabhakaran D, et al. Adult
521	metabolic syndrome and impaired glucose tolerance are associated with different patterns
522	of BMI gain during infancy data from the New Delhi birth cohort. Diabetes Care. Diabetes
523	Care; 2008;31:2349–56.
524	16. Srikanthan K, Feyh A, Visweshwar H, Shapiro JI, Sodhi K. Systematic review of metabolic
525	syndrome biomarkers: A panel for early detection, management, and risk stratification in
526	the West Virginian population. Int. J. Med. Sci. Ivyspring International Publisher; 2016. p.
527	25–38.
528	17. Kosek M, Haque R, Lima A, Babji S, Shrestha S, Qureshi S, et al. Fecal Markers of
529	Intestinal Inflammation and Permeability Associated with the Subsequent Acquisition of
530	Linear Growth Deficits in Infants. Am. J. Trop. Med. Hyg. [Internet]. 2013;88:390–6.
531	http://www.ajtmh.org/content/88/2/390: Accessed: 2015 Apr 15

18. Hartz J, Krauss RM, Göttsater M, Melander O, Nilsson P, Mietus-Snyder M. Lipoprotein 532

Particle Predictors of Arterial Stiffness after 17 Years of Follow Up: The Malmö Diet and 533

Cancer Study. Int. J. Vasc. Med. [Internet]. Hindawi Limited; 2020;2020. 534

35

535 https://pubmed.ncbi.nlm.nih.gov/32411471/: Accessed: 2020 Dec 14

536 19. Zlibut A, Agoston-Coldea L, Mocan T, Corina Bocsan I, Mocan L. Biomarkers in Metabolic

- 538 20. García-Jiménez S, Bernal Fernández G, Martínez Salazar MF, Monroy Noyola A, Toledano
- Jaimes C, Meneses Acosta A, et al. Serum Leptin is associated with metabolic syndrome in
- obese Mexican subjects. J. Clin. Lab. Anal. [Internet]. John Wiley and Sons Inc.; 2015;29:5–9.
- 541 http://www.ncbi.nlm.nih.gov/pubmed/24659484: Accessed: 2020 Apr 21
- 542 21. Supriya R, Tam BT, Yu AP, Lee PH, Lai CW, Cheng KK, et al. Adipokines demonstrate the
- 543 interacting influence of central obesity with other cardiometabolic risk factors of metabolic
- 544 syndrome in Hong Kong Chinese adults. PLoS One [Internet]. Public Library of Science;
- 545 2018;13:e0201585. http://www.ncbi.nlm.nih.gov/pubmed/30114249: Accessed: 2020

546 Apr 9

- 547 22. Esser N, Paquot N, Scheen AJ. Inflammatory markers and cardiometabolic diseases. Acta
 548 Clin. Belg. [Internet]. 2015;70:193–9. http://www.ncbi.nlm.nih.gov/pubmed/26103538:
 549 Accessed: 2019 Apr 12
- 550 23. Yoshinaga M, Sameshima K, Tanaka Y, Wada A, Hashiguchi J, Tahara H, et al. Adipokines
- and the prediction of the accumulation of cardiovascular risk factors or the presence of
- metabolic syndrome in elementary school children. Circ. J. [Internet]. 2008;72:1874–8.
- 553 http://www.ncbi.nlm.nih.gov/pubmed/18812676: Accessed: 2020 Apr 21
- 554 24. Moon YS, Kim DH, Song DK. Serum tumor necrosis factor-α levels and components of
- the metabolic syndrome in obese adolescents. Metabolism. [Internet]. 2004;53:863–7.

⁵³⁷ Syndrome. Ultim. Guid. to Insul. IntechOpen; 2019.

- http://www.ncbi.nlm.nih.gov/pubmed/15254878: Accessed: 2020 Apr 21
- 557 25. Colston JM, Peñataro Yori P, Moulton LH, Paredes Olortegui M, Kosek PS, Rengifo
- 558 Trigoso D, et al. Penalized regression models to select biomarkers of environmental enteric
- 559 dysfunction associated with linear growth acquisition in a Peruvian birth cohort. Azman
- 560 AS, editor. PLoS Negl. Trop. Dis. [Internet]. 2019;13:e0007851.
- 561 https://dx.plos.org/10.1371/journal.pntd.0007851: Accessed: 2019 Dec 5
- 562 26. Hossain M, Nahar B, Haque MA, Mondal D, Mahfuz M, Naila NN, et al. Serum Adipokines,
- 563 Growth Factors, and Cytokines Are Independently Associated with Stunting in Bangladeshi
- Children. Nutrients [Internet]. 2019;11. http://www.ncbi.nlm.nih.gov/pubmed/31394828:
- 565 Accessed: 2019 Sep 10
- 566 27. Colston JM, Peñataro Yori P, Colantuoni E, Moulton LH, Ambikapathi R, Lee G, et al. A
- 567 methodologic framework for modeling and assessing biomarkers of environmental
- 568 enteropathy as predictors of growth in infants: an example from a Peruvian birth cohort.
- Am. J. Clin. Nutr. [Internet]. American Society for Nutrition; 2017;106:245–55.
- 570 http://ajcn.nutrition.org/content/early/2017/06/07/ajcn.116.151886: Accessed: 2017
- 571 Jun 7
- 572 28. Teixeira TFS, Collado MC, Ferreira CLLF, Bressan J, Peluzio M do CG. Potential
- 573 mechanisms for the emerging link between obesity and increased intestinal permeability.
- 574 Nutr. Res. Elsevier; 2012. p. 637–47.
- 575 29. MAL-ED Network Investigators, The MAL-ED Network Investigators, MAL-ED Network
- 576 Investigators. The MAL-ED study: a multinational and multidisciplinary approach to
- 577 understand the relationship between enteric pathogens, malnutrition, gut physiology,

578	physical growth, cognitive development, and immune responses in infants and children up
579	to 2 years of. Clin. Infect. Dis. [Internet]. 2014;59 Suppl 4:S193-206.
580	http://www.ncbi.nlm.nih.gov/pubmed/25305287: Accessed: 2015 Dec 2
581	30. Yori PP, Lee G, Olortegui MP, Chavez CB, Flores JT, Vasquez AO, et al. Santa Clara de
582	Nanay: The MAL-ED Cohort in Peru. Clin. Infect. Dis. [Internet]. 2014;59:S310–6.
583	http://www.ncbi.nlm.nih.gov/pubmed/25305303: Accessed: 2016 Dec 27
584	31. Richard SA, Mccormick BJJ, Murray-Kolb LE, Lee GO, Seidman JC, Mahfuz M, et al.
585	Enteric dysfunction and other factors associated with attained size at 5 years: MAL-ED
586	birth cohort study findings. Am. J. Clin. Nutr. [Internet]. Oxford University Press;
587	2019;110:131–8. https://pubmed.ncbi.nlm.nih.gov/31127812/: Accessed: 2019 Sep 10
588	32. Lee GO, Kosek P, Lima AAM, Singh R, Yori PP, Olortegui MP, et al. Lactulose: mannitol
589	diagnostic test by HPLC and LC-MSMS platforms: considerations for field studies of
590	intestinal barrier function and environmental enteropathy. J. Pediatr. Gastroenterol. Nutr.
591	[Internet]. 2014;59:544–50.
592	http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4222705&tool=pmcentrez&r
593	endertype=abstract: Accessed: 2016 May 10
594	33. Kosek MN, Lee GO, Guerrant RL, Haque R, Kang G, Ahmed T, et al. Age and Sex
595	Normalization of Intestinal Permeability Measures for the Improved Assessment of
596	Enteropathy in Infancy and Early Childhood. J. Pediatr. Gastroenterol. Nutr. [Internet].
597	2017;65:31–9. http://www.ncbi.nlm.nih.gov/pubmed/28471910: Accessed: 2017 Aug 9
598	34. Liu J, Gratz J, Amour C, Nshama R, Walongo T, Maro A, et al. Optimization of Quantitative
599	PCR Methods for Enteropathogen Detection. Chan KH, editor. PLoS One [Internet]. Public

38

Library of Science; 2016;11:e0158199. http://dx.plos.org/10.1371/journal.pone.0158199:
Accessed: 2018 Mar 28

- 602 35. Houpt E, Gratz J, Kosek M, Zaidi AKM, Qureshi S, Kang G, et al. Microbiologic Methods
- Utilized in the MAL-ED Cohort Study. Clin. Infect. Dis. [Internet]. 2014;59:S225–32.
- 604 http://www.ncbi.nlm.nih.gov/pubmed/25305291: Accessed: 2016 Dec 1
- 605 36. Colston JM, Francois R, Pisanic N, Peñataro Yori P, McCormick BJJ, Olortegui MP, et al.
- 606 Effects of child and maternal Histo Blood Group Antigen status on symptomatic and
- asymptomatic enteric infections in early childhood. J. Infect. Dis. [Internet]. 2019;220:151-
- 608 62. https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiz072/5320520:
- 609 Accessed: 2019 Mar 1
- 610 37. Royston P. Multiple Imputation of Missing Values: Further Update of Ice, with an
- 611 Emphasis on Interval Censoring. Stata J. Promot. Commun. Stat. Stata. SAGE Publications;
- 612 2007;7:445-64.
- 38. StataCorp. Stata Statistical Software: Release 16. College Station, TX: StataCorp LLC;
 2019.
- 615 39. R Core Team. R: A language and environment for statistical computing. Vienna, Austria:
- 616 R Foundation for Statistical Computing; 2020. https://www.r-project.org/: Accessed
- 40. Di Palo DM, Garruti G, Di Ciaula A, Molina-Molina E, Shanmugam H, De Angelis M, et al.
- 618 Increased colonic permeability and lifestyles as contributing factors to obesity and liver
- 619 steatosis. Nutrients. MDPI AG; 2020;12.
- 41. E. S, M. L, C. I, A. G, Santis A. D, J. T. Intestinal Permeability in Non-alcoholic Fatty LIVER

39

621 Disease: The Gut-liver Axis. Rev. Recent Clin. Trials. Bentham Science Publishers Ltd.;

622 2015;9:141–7.

- 42. Penno G, Pucci L, Dell'Omo G, Lucchesi D, Miccoli R, Del Prato S, et al. Soluble CD40
- 624 ligand levels in essential hypertensive men: Evidence of a possible role of insulin
- resistance. Am. J. Hypertens. [Internet]. Oxford Academic; 2009;22:1007–13.
- https://academic.oup.com/ajh/article-lookup/doi/10.1038/ajh.2009.121: Accessed: 2021

627 Feb 4

- 43. Unek IT, Bayraktar F, Solmaz D, Ellidokuz H, Sisman AR, Yuksel F, et al. The levels of
- soluble CD40 ligand and C-reactive protein in normal weight, overweight and obese people.

630 Clin. Med. Res. [Internet]. Marshfield Clinic; 2010;8:89–95.

- http://www.clinmedres.org/content/8/2/89.full: Accessed: 2020 Dec 22
- 44. McCormick BJJ, Murray-Kolb LE, Lee GO, Schulze KJ, Ross AC, Bauck A, et al. Intestinal
- 633 permeability and inflammation mediate the association between nutrient density of
- 634 complementary foods and biochemical measures of micronutrient status in young children:
- Results from the MAL-ED study. Am. J. Clin. Nutr. [Internet]. Oxford University Press;
- 636 2019;110:1015–25. /pmc/articles/PMC6766446/?report=abstract: Accessed: 2021 Feb 2
- 45. Vilela EG, Torres HOG, Ferrari MLA, Lima AS, Cunha AS. Gut permeability to lactulose
- and mannitol differs in treated Crohn's disease and celiac disease patients and healthy
- 639 subjects. Brazilian J. Med. Biol. Res. [Internet]. Associacao Brasileira de Divulgacao
- 640 Cientifica; 2008;41:1105–9. www.bjournal.com.br: Accessed: 2021 Feb 4
- 46. Di Sabatino A, Rovedatti L, Vetrano S, Vidali F, Biancheri P, Rescigno M, et al.
- 642 Involvement of CD40-CD40 Ligand in uncomplicated and refractory celiac disease. Am. J.

	(which was not certilied by peer review) is the author/funder, who has granted medexity a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
	40
643	Gastroenterol. [Internet]. Am J Gastroenterol; 2011;106:519–27.
644	https://pubmed.ncbi.nlm.nih.gov/21139574/: Accessed: 2021 Feb 4
645	47. Ludwiczek O, Kaser A, Tilg H. Plasma levels of soluble CD40 ligand are elevated in
646	inflammatory bowel diseases. Int. J. Colorectal Dis. [Internet]. Springer Verlag;
647	2003;18:142–7. https://pubmed.ncbi.nlm.nih.gov/12548417/: Accessed: 2021 Feb 4
648	48. Zanetti M, Bosutti A, Ferreira C, Vinci P, Biolo G, Fonda M, et al. Circulating pentraxin 3
649	levels are higher in metabolic syndrome with subclinical atherosclerosis: Evidence for
650	association with atherogenic lipid profile. Clin. Exp. Med. [Internet]. Springer; 2009;9:243-
651	8. https://link.springer.com/article/10.1007/s10238-009-0039-z: Accessed: 2020 Dec 22
652	49. Deo R, Khera A, McGuire DK, Murphy SA, De P. Meo Neto J, Morrow DA, et al. Association
653	among plasma levels of monocyte chemoattractant protein-1, traditional cardiovascular
654	risk factors, and subclinical atherosclerosis. J. Am. Coll. Cardiol. 2004;44:1812–8.
655	50. Zhang X, Yeung DCY, Karpisek M, Stejskal D, Zhou ZG, Liu F, et al. Serum FGF21 levels
656	are increased in obesity and are independently associated with the metabolic syndrome in
657	humans. Diabetes [Internet]. American Diabetes Association Inc.; 2008;57:1246–53.
658	http://dx.doi.org/10.2337/db07-1476.: Accessed: 2020 Dec 22
659	51. Wu G, Liu Y, Liu Y, Zhang L, Zhao H, Liu L, et al. FGF 21 deficiency slows gastric
660	emptying and reduces initial blood alcohol concentration in mice exposed to acute alcohol
661	in fasting state. Biochem. Biophys. Res. Commun. [Internet]. Elsevier B.V.; 2018;497:46–50.

52. Castro APP, Hermsdorff HHM, Milagres LC, Albuquerque FM de, Filgueiras M de S, 663

/pmc/articles/PMC6044432/: Accessed: 2021 Feb 10

Rocha NP, et al. Increased ApoB/ApoA1 ratio is associated with excess weight, body

adiposity, and altered lipid profile in children. J. Pediatr. (Rio. J). Elsevier Editora Ltda;

666	2019;95:238–46.
667	53. Sierra-Johnson J, Romero-Corral A, Somers VK, Lopez-Jimenez F, Walldius G, Hamsten
668	A, et al. ApoB/apoA-I ratio: an independent predictor of insulin resistance in US non-
669	diabetic subjects. Eur. Heart J. Oxford Academic; 2007;28:2637–43.
670	54. Hansberry DR, Shah K, Agarwal P, Agarwal N. Fecal Myeloperoxidase as a Biomarker for
671	Inflammatory Bowel Disease. Cureus [Internet]. Cureus, Inc.; 2017;9.
672	/pmc/articles/PMC5332167/?report=abstract: Accessed: 2021 Feb 4
673	55. Kruidenier L, Kuiper I, Lamers CBHW, Verspaget HW. Intestinal oxidative damage in
674	inflammatory bowel disease: Semi-quantification, localization, and association with
675	mucosal antioxidants. J. Pathol. [Internet]. J Pathol; 2003;201:28–36.
676	https://pubmed.ncbi.nlm.nih.gov/12950014/: Accessed: 2021 Feb 26
677	56. Marrocco I, Altieri F, Peluso I. Measurement and Clinical Significance of Biomarkers of
678	Oxidative Stress in Humans. Oxid. Med. Cell. Longev. Hindawi Limited; 2017.
679	57. Damås JK, Otterdal K, Yndestad A, Aass H, Solum NO, Frø SS, et al. Soluble CD40 ligand
680	in pulmonary arterial hypertension: Possible pathogenic role of the interaction between
681	platelets and endothelial cells. Circulation [Internet]. Lippincott Williams & Wilkins;
682	2004;110:999–1005. http://www.circulationaha.org: Accessed: 2021 Feb 26
683	58. Tan BK, Adya R, Randeva HS. Omentin: A Novel Link Between Inflammation, Diabesity,
684	and Cardiovascular Disease. Trends Cardiovasc. Med. Elsevier; 2010. p. 143–8.

42

- 685 59. Watanabe T, Watanabe-Kominato K, Takahashi Y, Kojima M, Watanabe R. Adipose
- Tissue-Derived Omentin-1 Function and Regulation. Compr. Physiol. [Internet]. Hoboken,
- 687 NJ, USA: John Wiley & Sons, Inc.; 2017. p. 765–81.
- 688 http://doi.wiley.com/10.1002/cphy.c160043: Accessed: 2021 Feb 4
- 689 60. Binti Kamaruddin NA, Fong LY, Tan JJ, Abdullah MNH, Singh Cheema M, Bin Yakop F, et
- al. Cytoprotective Role of Omentin Against Oxidative Stress-Induced Vascular Endothelial
- 691 Cells Injury. Molecules. MDPI AG; 2020;25:2534.
- 692 61. Sznurkowska K, Luty J, Bryl E, Witkowski JM, Hermann-Okoniewska B, Landowski P, et
- al. Enhancement of circulating and intestinal T regulatory cells and their expression of
- helios and neuropilin-1 in children with inflammatory bowel disease. J. Inflamm. Res.
- 695 [Internet]. Dove Medical Press Ltd; 2020;13:995–1005. /pmc/articles/PMC7705274/:
- 696 Accessed: 2021 Feb 24
- 697 62. Barker DJP, Osmond C, Forsén TJ, Kajantie E, Eriksson JG. Trajectories of Growth among

698 Children Who Have Coronary Events as Adults. N. Engl. J. Med. Massachusetts Medical

- 699 Society; 2005;353:1802–9.
- 63. Bhargava SK, Sachdev HS, Fall CHD, Osmond C, Lakshmy R, Barker DJP, et al. Relation of
- 701 Serial Changes in Childhood Body-Mass Index to Impaired Glucose Tolerance in Young
- Adulthood. N. Engl. J. Med. New England Journal of Medicine (NEJM/MMS); 2004;350:865–
- 703 75.
- 64. Chamekh M. CD40-CD40L interaction in immunity against protozoan infections. J.
- 705 Biomed. Biotechnol. Hindawi Limited; 2007.
- 706 /pmc/articles/PMC1874672/?report=abstract: Accessed: 2021 Feb 5

43

707	65. Guo X, Roberts MR, Becker SM, Podd B, Zhang Y, Chua SC, et al. Leptin signaling in
708	intestinal epithelium mediates resistance to enteric infection by Entamoeba histolytica.
709	Mucosal Immunol. [Internet]. NIH Public Access; 2011;4:294–303.
710	/pmc/articles/PMC3079783/?report=abstract: Accessed: 2021 Feb 5
711	66. Lõhmus M, Moalem S, Björklund M. Leptin, a tool of parasites? Biol. Lett. [Internet].
712	Royal Society; 2012;8:849–52. /pmc/articles/PMC3440990/?report=abstract: Accessed:
713	2021 Feb 5
714	67. Mackey-Lawrence NM, Petri WA. Leptin and mucosal immunity. Mucosal Immunol. NIH
715	Public Access; 2012. p. 472–9. /pmc/articles/PMC3425733/?report=abstract: Accessed:
716	2021 Feb 5
717	68. Yahya RS, Awad SI, El-Baz HA, Atia G, Kizilbash NA. Enteric parasites can disturb leptin
718	and adiponectin levels in children. Arch. Med. Sci. [Internet]. Termedia Publishing House
719	Ltd.; 2018;14:101–6. /pmc/articles/PMC5778414/?report=abstract: Accessed: 2021 Feb 5
720	69. Chan JL, Blüher S, Yiannakouris N, Suchard MA, Kratzsch J, Mantzoros CS. Regulation of
721	circulating soluble leptin receptor levels by gender, adiposity, sex steroids, and leptin
722	observational and interventional studies in humans. Diabetes [Internet]. American
723	Diabetes Association Inc.; 2002;51:2105–12.
724	https://diabetes.diabetesjournals.org/content/51/7/2105: Accessed: 2021 Feb 5
725	70. Long KZ, Santos JI, Garcia TE, Haas M, Firestone M, Bhagwat J, et al. Vitamin A
726	supplementation reduces the monocyte chemoattractant protein-1 intestinal immune
727	response of Mexican children. J. Nutr. [Internet]. American Institute of Nutrition;

728 2006;136:2600–5. https://academic.oup.com/jn/article/136/10/2600/4746703:

44

- 729 Accessed: 2021 Feb 5
- 730 71. Lechner CJ, Komander K, Hegewald J, Huang X, Gantin RG, Soboslay PT, et al. Cytokine
- and chemokine responses to helminth and protozoan parasites and to fungus and mite
- allergens in neonates, children, adults, and the elderly. Immun. Ageing [Internet]. BioMed
- 733 Central; 2013;10:29. /pmc/articles/PMC3720251/: Accessed: 2021 Feb 23
- 734 72. Batterham RL, Le Roux CW, Cohen MA, Park AJ, Ellis SM, Patterson M, et al. Pancreatic
- polypeptide reduces appetite and food intake in humans. J. Clin. Endocrinol. Metab.
- 736 [Internet]. J Clin Endocrinol Metab; 2003;88:3989–92.
- 737 https://pubmed.ncbi.nlm.nih.gov/12915697/: Accessed: 2021 Feb 5
- 73. Frühbeck G, Catalán V, Rodríguez A, Ramírez B, Becerril S, Salvador J, et al. Adiponectin-
- ratio is a functional biomarker of adipose tissue inflammation. Nutrients [Internet].
- 740 MDPI AG; 2019;11. /pmc/articles/PMC6412349/?report=abstract: Accessed: 2021 Feb 8
- 74. Soliman A, De Sanctis V, Elalaily R. Nutrition and pubertal development. Indian J.
- 742 Endocrinol. Metab. Medknow Publications; 2014. p. S39–47. /pmc/articles/PMC4266867/:
- 743 Accessed: 2021 Feb 10